- Home
- Equipment
- south korea
- drug developers
Show results for
Refine by
Drug Developers Equipment Supplied In South Korea
10 equipment items found
by:KoBioLabs based inGwanak-ro, Gwanak-gu, SOUTH KOREA
New Drug Development Focusing on Immune/Metabolic/Neurological. ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
Agonist refers to substances that activate a specific target protein. It can easily be viewed as the opposite of inhibitor. Until now, Deargen's drug-target interaction (DTI) was predicted based on the binding affinity between the substance and the target protein, which causes barrier to distinguish between the inhibition and activation activity. In addition, the demand for ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
PROTAC is composed of a protein of interest, a ligand that binds to the E3 ligase, and a linker that connects the two. PROTAC is emerging as a next-generation platform for new drug development that overcomes the problems of drug resistance and “Undruggable targets” of existing target therapies whose main purpose was to inhibit the ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
MolEQ designs novel compounds by optimizing multiple properties such as efficacy and toxicity of a lead ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
To hinder or inhibit the function of proteins that cause disease, many pharmaceutical companies develop drugs called inhibitors. Each of the 20,000 proteins in the human body has its own unique functions. Depending on the function of the protein, it can be classified into enzyme proteins, ion channel proteins, transport proteins, defense proteins, and structural ...
by:Theramx Inc. based inSeongnam-si, SOUTH KOREA
Drug delivery platform technology designed to maximize efficacy while simultaneously minimizing side effects of existing drugs by delivery to desired ...
Manufactured by:MitoImmune Therapeutics Inc. based inGangnam-gu, SOUTH KOREA
The blood-brain barrier (BBB) penetrating technology is essential to develop drugs for neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, ALS, and Huntington’s disease, which have high unmet medical needs. MitoImmune has developed BIM Technology, a central nervous system target technology, and is conducting R&D ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
DearDTI presents drug candidates with a good efficacy by predicting the binding affinity, based on information about the compound-protein ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
WX presents biomarkers, based on raw transcriptome data. It is an artificial intelligence technology that can predict biomarkers, prognostic biomarkers and even the mode of action (MOA) of disease ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology. It specializes in genome data analysis, biomarker prediction, molecule selection and optimization. DEARGEN discovers new disease targets with Dr.UG and further realizes precision medicine by designing small molecules for new ...